Paeonol Inhibits Pancreatic Cancer Cell Migration and Invasion Through the Inhibition of TGF-β1/Smad Signaling and Epithelial-Mesenchymal-Transition

References

• Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388(10039):73–85. doi:10.1016/S0140-6736(16)00141-026830752
   PubMed Web of Science ®Google Scholar
• Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607–620. doi:10.1016/S0140-6736(10)62307-021620466
   PubMed Web of Science ®Google Scholar
• Manji GA, Olive KP, Saenger YM, Oberstein P. Current and emerging therapies in metastatic pancreatic cancer. Clin Cancer Res. 2017;23(7):1670–1678. doi:10.1158/1078-0432.CCR-16-231928373365
   PubMed Web of Science ®Google Scholar
• Heerboth S, Housman G, Leary M, et al. EMT and tumor metastasis. Clin Transl Med. 2015;4:6. doi:10.1186/s40169-015-0048-325852822
   PubMed Web of Science ®Google Scholar
• Zhou P, Li B, Liu F, et al. The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer. Mol Cancer. 2017;16(1):52. doi:10.1186/s12943-017-0624-928245823
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196. doi:10.1038/nrm375824556840
   PubMed Web of Science ®Google Scholar
• Jolly MK, Boareto M, Huang B, et al. Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. Front Oncol. 2015;5:155. doi:10.3389/fonc.2015.0015526258068
   PubMed Web of Science ®Google Scholar
• Lindsey S, Langhans SA. Crosstalk of oncogenic signaling pathways during epithelial-mesenchymal transition. Front Oncol. 2014;4:358. doi:10.3389/fonc.2014.0035825566498
   PubMedGoogle Scholar
• Lyu ZK, Li CL, Jin Y, et al. Paeonol exerts potential activities to inhibit the growth, migration and invasion of human gastric cancer BGC823 cells via downregulating MMP2 and MMP9. Mol Med Rep. 2017;16(5):7513–7519. doi:10.3892/mmr.2017.757628944890
   PubMed Web of Science ®Google Scholar
• Sun Z, Du J, Hwang E, Yi TH. Paeonol extracted from paeonia suffruticosa Andr. ameliorated UVB-induced skin photoaging via DLD/Nrf2/ARE and MAPK/AP-1 pathway. Phytother Res. 2018;32(9):1741–1749. doi:10.1002/ptr.610029748977
   PubMed Web of Science ®Google Scholar
• Guo L, Liang J, Yang Q. Determination of paeonol in the root of cynanchum paniculatum (Bge.) Kitag. by gas chromatography. Zhongguo Zhong Yao Za Zhi. 1996;21(8):484–485, 511.9642412
   PubMedGoogle Scholar
• Lei Y, Li HX, Jin WS, et al. The radiosensitizing effect of paeonol on lung adenocarcinoma by augmentation of radiation-induced apoptosis and inhibition of the PI3K/Akt pathway. Int J Radiat Biol. 2013;89(12):1079–1086. doi:10.3109/09553002.2013.82505823875954
   PubMed Web of Science ®Google Scholar
• Zhou HM, Sun QX, Cheng Y. Paeonol enhances the sensitivity of human ovarian cancer cells to radiotherapy-induced apoptosis due to downregulation of the phosphatidylinositol-3-kinase/Akt/phosphatase and tensin homolog pathway and inhibition of vascular endothelial growth factor. Exp Ther Med. 2017;14(4):3213–3220. doi:10.3892/etm.2017.487728912871
   PubMed Web of Science ®Google Scholar
• Yin J, Wu N, Zeng F, Cheng C, Kang K, Yang H. Paeonol induces apoptosis in human ovarian cancer cells. Acta Histochem. 2013;115(8):835–839. doi:10.1016/j.acthis.2013.04.00423768958
   PubMed Web of Science ®Google Scholar
• Fu J, Yu L, Luo J, Huo R, Zhu B. Paeonol induces the apoptosis of the SGC7901 gastric cancer cell line by downregulating ERBB2 and inhibiting the NFkappaB signaling pathway. Int J Mol Med. 2018;42(3):1473–1483. doi:10.3892/ijmm.2018.370429845222
   PubMed Web of Science ®Google Scholar
• Li N, Fan LL, Sun GP, et al. Paeonol inhibits tumor growth in gastric cancer in vitro and in vivo. World J Gastroenterol. 2010;16(35):4483–4490. doi:10.3748/wjg.v16.i35.448320845518
   PubMed Web of Science ®Google Scholar
• Li M, Tan SY, Wang XF. Paeonol exerts an anticancer effect on human colorectal cancer cells through inhibition of PGE(2) synthesis and COX-2 expression. Oncol Rep. 2014;32(6):2845–2853. doi:10.3892/or.2014.354325322760
   PubMed Web of Science ®Google Scholar
• Li M, Tan SY, Zhang J, You HX. Effects of paeonol on intracellular calcium concentration and expression of RUNX3 in LoVo human colon cancer cells. Mol Med Rep. 2013;7(5):1425–1430. doi:10.3892/mmr.2013.137223504038
   PubMed Web of Science ®Google Scholar
• Ou Y, Li Q, Wang J, Li K, Zhou S. Antitumor and apoptosis induction effects of paeonol on mice bearing EMT6 breast carcinoma. Biomol Ther (Seoul). 2014;22(4):341–346. doi:10.4062/biomolther.2013.10625143814
   PubMed Web of Science ®Google Scholar
• Cai J, Chen S, Zhang W, et al. Paeonol reverses paclitaxel resistance in human breast cancer cells by regulating the expression of transgelin 2. Phytomedicine. 2014;21(7):984–991. doi:10.1016/j.phymed.2014.02.01224680370
   PubMed Web of Science ®Google Scholar
• Saahene RO, Wang J, Wang ML, Agbo E, Pang D. The antitumor mechanism of paeonol on CXCL4/CXCR3-B signals in breast cancer through induction of tumor cell apoptosis. Cancer Biother Radiopharm. 2018;33(6):233–240. doi:10.1089/cbr.2018.245029847158
   PubMed Web of Science ®Google Scholar
• Zhang W, Cai J, Chen S, et al. Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway. Mol Med Rep. 2015;12(1):1506–1514. doi:10.3892/mmr.2015.346825760096
   PubMed Web of Science ®Google Scholar
• Fan L, Song B, Sun G, Ma T, Zhong F, Wei W. Endoplasmic reticulum stress-induced resistance to doxorubicin is reversed by paeonol treatment in human hepatocellular carcinoma cells. PLoS One. 2013;8(5):e62627. doi:10.1371/journal.pone.006262723658755
   PubMed Web of Science ®Google Scholar
• Chen B, Ning M, Yang G. Effect of paeonol on antioxidant and immune regulatory activity in hepatocellular carcinoma rats. Molecules. 2012;17(4):4672–4683. doi:10.3390/molecules1704467222522397
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kim SA, Lee HJ, et al. Paeonol oxime inhibits bFGF-induced angiogenesis and reduces VEGF levels in fibrosarcoma cells. PLoS One. 2010;5(8):e12358. doi:10.1371/journal.pone.001235820808805
   PubMed Web of Science ®Google Scholar
• Horng CT, Shieh PC, Tan TW, Yang WH, Tang CH. Paeonol suppresses chondrosarcoma metastasis through up-regulation of miR-141 by modulating PKCdelta and c-Src signaling pathway. Int J Mol Sci. 2014;15(7):11760–11772. doi:10.3390/ijms15071176024992595
   PubMed Web of Science ®Google Scholar
• Tamburrino A, Piro G, Carbone C, Tortora G, Melisi D. Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Front Pharmacol. 2013;4:56. doi:10.3389/fphar.2013.0005623641216
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Alvarez R, Gallego J, et al. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Clin Transl Oncol. 2017;19(6):667–681. doi:10.1007/s12094-016-1594-x27995549
   PubMed Web of Science ®Google Scholar
• Peixoto RD, Speers C, McGahan CE, Renouf DJ, Schaeffer DF, Kennecke HF. Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Cancer Med. 2015;4(8):1171–1177. doi:10.1002/cam4.45925891650
   PubMed Web of Science ®Google Scholar
• Barrallo-Gimeno A, Nieto MA. The snail genes as inducers of cell movement and survival: implications in development and cancer. Development. 2005;132(14):3151–3161. doi:10.1242/dev.0190715983400
   PubMed Web of Science ®Google Scholar
• Aigner K, Dampier B, Descovich L, et al. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene. 2007;26(49):6979–6988. doi:10.1038/sj.onc.121050817486063
   PubMed Web of Science ®Google Scholar
• Gaianigo N, Melisi D, Carbone C. EMT and treatment resistance in pancreatic cancer. Cancers (Basel). 2017;9(9):122. doi:10.3390/cancers9090122
   PubMed Web of Science ®Google Scholar
• Nakajima S, Doi R, Toyoda E, et al. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res. 2004;10(12 Pt 1):4125–4133. doi:10.1158/1078-0432.CCR-0578-0315217949
   PubMed Web of Science ®Google Scholar
• Mrozik KM, Blaschuk OW, Cheong CM, Zannettino ACW, Vandyke K. N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer. BMC Cancer. 2018;18(1):939. doi:10.1186/s12885-018-4845-030285678
   PubMed Web of Science ®Google Scholar
• Wang S, Huang S, Sun YL. Epithelial-mesenchymal transition in pancreatic cancer: a review. Biomed Res Int. 2017;2017:2646148. doi:10.1155/2017/264614829379795
   PubMed Web of Science ®Google Scholar
• David CJ, Huang YH, Chen M, et al. TGF-beta tumor suppression through a lethal EMT. Cell. 2016;164(5):1015–1030. doi:10.1016/j.cell.2016.01.00926898331
   PubMed Web of Science ®Google Scholar
• O’Connor JW, Gomez EW. Biomechanics of TGFbeta-induced epithelial-mesenchymal transition: implications for fibrosis and cancer. Clin Transl Med. 2014;3:23. doi:10.1186/2001-1326-3-2325097726
   PubMedGoogle Scholar
• Moustakas A, Heldin CH. Mechanisms of TGFbeta-induced epithelial-mesenchymal transition. J Clin Med. 2016;5:7. doi:10.3390/jcm5070063
   PubMed Web of Science ®Google Scholar
• Xu W, Yang Z, Lu N. A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adh Migr. 2015;9(4):317–324. doi:10.1080/19336918.2015.101668626241004
   PubMed Web of Science ®Google Scholar
• Haque S, Morris JC. Transforming growth factor-beta: a therapeutic target for cancer. Hum Vaccin Immunother. 2017;13(8):1741–1750. doi:10.1080/21645515.2017.132710728575585
   PubMed Web of Science ®Google Scholar
• Zhang L, Tao L, Shi T, et al. Paeonol inhibits B16F10 melanoma metastasis in vitro and in vivo via disrupting proinflammatory cytokines-mediated NF-kappaB and STAT3 pathways. IUBMB Life. 2015;67(10):778–788. doi:10.1002/iub.143526452780
   PubMed Web of Science ®Google Scholar
• Sun GP, Wang H, Xu SP, et al. Anti-tumor effects of paeonol in a HepA-hepatoma bearing mouse model via induction of tumor cell apoptosis and stimulation of IL-2 and TNF-alpha production. Eur J Pharmacol. 2008;584(2–3):246–252. doi:10.1016/j.ejphar.2008.02.01618329639
   PubMed Web of Science ®Google Scholar
• Ellenrieder V, Hendler SF, Boeck W, et al. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res. 2001;61(10):4222–4228.11358848
   PubMed Web of Science ®Google Scholar
• Wang H, Wu J, Zhang Y, et al. Transforming growth factor beta-induced epithelial-mesenchymal transition increases cancer stem-like cells in the PANC-1 cell line. Oncol Lett. 2012;3(1):229–233. doi:10.3892/ol.2011.44822740886
   PubMed Web of Science ®Google Scholar
• Lebrun JJ. The dual role of TGFbeta in human cancer: from tumor suppression to cancer metastasis. ISRN Mol Biol. 2012;2012:381428.27340590
   PubMedGoogle Scholar
• Kashima R, Hata A. The role of TGF-beta superfamily signaling in neurological disorders. Acta Biochim Biophys Sin (Shanghai). 2018;50(1):106–120. doi:10.1093/abbs/gmx12429190314
   PubMed Web of Science ®Google Scholar
• Pardali E, Ten Dijke P. TGFbeta signaling and cardiovascular diseases. Int J Biol Sci. 2012;8(2):195–213. doi:10.7150/ijbs.8.19522253564
   PubMed Web of Science ®Google Scholar
• Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 2006;25(3):435–457. doi:10.1007/s10555-006-9006-216951986
   PubMed Web of Science ®Google Scholar
• Nie D, Sun H, Shi Z, Zhou X. The effects of combination of paeonol and PNS on TGF-β/smad pathway in ventricular remodeling after myocardial infarction in rats. Tianjin Med J. 2016;44(4):449–452.
   Google Scholar
• Wu S, Liu L, Yang S, et al. Paeonol alleviates CCl4-induced liver fibrosis through suppression of hepatic stellate cells activation via inhibiting the TGF-beta/smad3 signaling. Immunopharmacol Immunotoxicol. 2019;41(3):438–445. doi:10.1080/08923973.2019.161342731119954
   PubMed Web of Science ®Google Scholar